Sarepta Therapeutics, Inc.’s SRPT share price has surged by 6.43%, which has investors questioning if this is right time to sell.

Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – ...

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the ...

This designation is pivotal for developing DYNE-251, which is currently being evaluated in the Phase I/II DELIVER trial for DMD individuals amenable to exon 51 skipping. The trial’s long-term clinical ...

For exclusive news and updates, subscribe to our NCIS Newsletter: The NCIS franchise keeps growing, but even as it does, some of its shows do say goodbye. The mothership, however, isn’t going ...

DYNE-251 is being evaluated in the Phase 1/2 DELIVER global clinical trial in individuals with DMD who are amenable to exon 51 skipping. Long-term clinical data from the ongoing DELIVER trial of ...

Under the theme “Together We Thrive,” the event will share information on research and resources for families affected by Duchenne muscular dystrophy. Registration is open and participants can attend ...

WASHINGTON — House and Senate Democrats are at a low ebb among Americans under 30, with just 23% approving of party lawmakers in the wake of President Trump’s return to the White House.

Today’s Birthday (04/23/25). Grow financial prosperity this year. Collaborate for shared fun and ease. Adapt around summer changes with a private recharge, before exciting autumn social ...

Duchenne muscular dystrophy (DMD), my lifelong companion, has undoubtedly influenced our journey together. But instead of posing a challenge, it’s brought us closer in profound and surprising ways.